Trulieve 10-Q: Q3 Swings to $869K Net Income, $326.7M Cash, $403.3M Harvest Charge
TRLV has more than doubled off its 52-week low of $4.616.
Summary
Trulieve's Q3 10-Q shows a $869 thousand profit attributable to shareholders on $230.2 million of revenue, $326.7 million of cash, and a $403.3 million non-cash Harvest deconsolidation charge driving the nine-month loss. The $625.4 million uncertain tax liability tied to Section 280E remains the biggest balance-sheet risk.
Key Events · Earnings and Guidance · TRLV
-
Q3 Swings to Small GAAP Profit
Net income attributable to common shareholders was $869 thousand versus a $26.8 million loss in Q3 2025, on revenue of $230.2 million (down 20% year over year) and gross margin of 64.3%.
-
Harvest Charge Drives Nine-Month Loss
The $403.0 million nine-month net loss is almost entirely the $403.3 million non-cash loss on the June 3, 2026 Harvest deconsolidation; the company retains a $146.1 million equity-method stake and $21.3 million MSA receivable.
-
Cash Builds, Mortgage Repaid
Cash and equivalents reached $326.7 million at September 30, 2026 from $255.5 million at year-end, with $183.3 million of nine-month operating cash flow; on October 7, 2026 the company repaid $65.1 million of mortgage notes due 2028.
-
$625.4M Tax Liability Still Open
Uncertain tax position liabilities were $625.4 million, $610.0 million tied to the IRC Section 280E position, including $104.8 million of accrued interest; the IRS proposed $38.1 million of penalties that are not accrued and are being contested.
Analysis · TRLV · Life Sciences
The headline numbers were already out this morning, but the 10-Q is where the balance sheet and the risks live. Trulieve swung to a small GAAP profit in Q3 — $869 thousand attributable to shareholders against a $26.8 million loss a year ago — while revenue fell 20% to $230.2 million, almost entirely because Harvest was deconsolidated on June 3, 2026 and no longer contributes. The nine-month $403.0 million net loss is that same deconsolidation charge ($403.3 million, non-cash), not an operating deterioration. What matters for the thesis: $326.7 million of cash against $289 million of debt, $183.3 million of nine-month operating cash flow, and a $65.1 million mortgage repaid on October 7, 2026 that removes a 2028 maturity. The overhang is the $625.4 million uncertain tax position liability, $610.0 million of it tied to the Section 280E position, plus $38.1 million of IRS-proposed penalties the company has not accrued and is contesting. The DEA registrations for substantially all dispensaries under the Schedule III framework are the reason no new 280E positions were booked for 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRLV was trading at $11.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $4.62 to $13.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.